BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:ICTP Colloquium: Development of Novel Radionuclides for New Emergi
 ng Medical Applications 
DTSTART;VALUE=DATE-TIME:20261104T150000Z
DTEND;VALUE=DATE-TIME:20261104T163000Z
DTSTAMP;VALUE=DATE-TIME:20261114T232816Z
UID:indico-event-11554@ictp.it
DESCRIPTION:\n	Syed M. Qaim\n	(Institute of Neuroscience and Medicine\, Ge
 rmany)\n \n\n	Syed Muhammad Qaim is a retired Professor at the Forschungs
 zentrum Jülich\, Germany. He has been engaged in nuclear research for mor
 e than 60 years\, working in the areas of fundamental nuclear chemistry\, 
 nuclear data for applications and medical radionuclides. He has published 
 more than 430 papers\, written several books  and has given invited talks
  at more than 100 international conferences. Besides his normal research a
 nd teaching duties\, he has been actively  engaged in the propagation of 
 science through his long associations with the international bodies OECD-N
 EA (Paris)\,  IAEA (Vienna) and  ICTP (Trieste). He has also contributed
  appreciably  to the development of science in the Third World Countries.
  For his sustained seminal contributions he  received various types of aw
 ards and honours  in about 10 countries of the world.\n \nAbsract:\n\n	T
 he production technology of reactor- and cyclotron-based radionuclides\, r
 outinely used in patient care\, encompassing about 60 million cases worldw
 ide per year\, is generally well established. However\, to meet demands of
  some new emerging medical applications\, such as bimodal imaging\, theran
 ostic approach or radioimmunotherapy\, novel radionuclides with versatile 
 labelling chemistry are needed. In great demand are presently longer-lived
  non-standard positron emitters for diagnosis and low-energy highly-ionisi
 ng β-- and α-particle emitters for therapy Special interest lies present
 ly in the radionuclide targeted therapy. This talk gives an overview of ne
 w research trends in production of novel medical radionuclides. The releva
 nt areas of investigation include nuclear data\, high current irradiation 
 technology\, chemical processing and quality assurance of the radioactive 
 product. A few examples from each area will be given\, based on the use of
  the following existing and emerging technical facilities.\n\n		Research r
 eactors. The aim is to produce several therapeutic radionuclides with high
  specific activity (e.g. 47Sc\, 153Sm\, 161Tb\, etc.). Even power reactors
  are being considered.\n	\n		Small medical cyclotrons (E<20 MeV). Extensiv
 e new installations are taking place worldwide. Efforts are underway to pr
 oduce non-standard positron emitters (e.g. 64Cu\, 68Ga\, 86Y\, 89Zr) at th
 ose cyclotrons using isotopically highly-enriched materials and sophistica
 ted targetry.\n	\n		Medium-sized cyclotrons. High-intensity α-particle be
 ams are being developed\, and work is in progress to produce large quantit
 ies of 211At for α-therapy\,\n	\n		Intermediate energy cyclotrons/acceler
 ators. Use of (p\,x) reactions is being intensified to produce several rad
 ionuclides (e.g. 67Cu\,225Ac\, etc.)\; also (p\,spall) process in combinat
 ion with on-line mass separation is occasionally used (e.g. 152Tb). Anothe
 r approach is to generate d(Be) fast neutrons and use them to induce (n\,2
 n) or (n\,xp) reactions to produce therapeutic radionuclides (e.g. 225Ac\,
  67Cu\, etc.)\n	\n		LINACs. High-intensity electron beams are being develo
 ped to generate high energy photons to induce (γ\,n) reaction products\, 
 e.g. 99Mo/99mTc and 225Ra/225Ac) or (γ\,p) reaction products (e.g. 47Sc a
 nd 67Cu).\n\nWherever possible\, an overall appraisal of recent advances w
 ill be given.\n\n	- - -\n	 \n	Refreshments will be served in the lobby of
  the Leonardo Building after the talk.\n	 \n	- - -\n	Video recording avai
 lable here\n	 \n\n//indico.ictp.it/event/11554/
LOCATION:Budinich Lecture Hall (Leonardo Building) and via streaming
URL://indico.ictp.it/event/11554/
END:VEVENT
END:VCALENDAR